One of our clients published preclinical data on NASH-fibrosis on Scientific Reports
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Scientific Reports:
Title: “Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan”
Telmisartan is a potential treatment for NASH/NAFLD due to its ability to improve inflammation and decrease hepatic fat accumulation via modulation of PPAR-g, and to suppress liver fibrosis by blocking angiotensin II receptors.
This paper reports the mechanism of action of these effects of Telmisartan.
Hepatic transcriptomic analyses revealed that the amelioration of NASH possibly occurred via the regulation of inflammation- and fibrosis-related responses.